Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394493 | 0.81 | GLA (0.43) | NPC1RAB9ASMYD3SMN1; SMN2GLA | |
| SCHEMBL2394499 | 0.81 | SMN1; SMN2 (0.52) | NPC1RAB9ASMYD3SMN1; SMN2GLA | |
| SCHEMBL2391473 | 0.80 | NPC1 (0.40) | NPC1RAB9ASMYD3SMN1; SMN2GLA | |
| SCHEMBL2391475 | 0.80 | NPC1 (0.40) | NPC1RAB9ASMYD3SMN1; SMN2GLA | |
| SCHEMBL14721548 | 0.78 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GLAHPGD | |
| SCHEMBL2707315 | 0.76 | S100A4 (0.34) | NPC1RAB9AGLATAS1R3TAS1R1 | |
| SCHEMBL18413476 | 0.76 | RAB9A (0.33) | NPC1RAB9ASMN1; SMN2GLATAS1R3 | |
| SCHEMBL14961948 | 0.76 | S100A4 (0.34) | NPC1RAB9AGLATAS1R3TAS1R1 | |
| SCHEMBL31435866 | 0.74 | HDAC8 (0.49) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18670611 | 0.73 | SMN1; SMN2 (0.36) | NPC1RAB9ASMYD3SMN1; SMN2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539335-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| EP-2539335-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2539335-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | Syngenta Participations AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104089-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104089-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206633-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE DERIVATIVES | CYP1A2, CHRM1, CYP1A1 | NPC1 3640/4885RAB9A 2340/4885SMYD3 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.